Analyzing immune and nutrition factors in advanced gastric cancer before surgery
The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments: Observational Cohort Study
This study looks at how treatments before surgery, like chemotherapy, affect the immune system and nutrition in people with advanced gastric cancer to see how these factors relate to their recovery and outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Sex | All |
| Sponsor | Peking University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT03493880 on ClinicalTrials.gov |
What this trial studies
This observational study investigates how preoperative treatments like chemotherapy and chemoradiotherapy affect the immune and nutrition indices in patients with advanced gastric cancer. It aims to clarify the clinical significance of these indices, which include various ratios and scores that reflect systemic inflammation and nutritional status. By analyzing these factors, the study seeks to understand their correlation with patient prognosis and treatment outcomes.
Who should consider this trial
Good fit: Ideal candidates are patients with histologically confirmed advanced gastric or esophagogastric adenocarcinoma who have received neoadjuvant chemotherapy or chemoradiotherapy.
Not a fit: Patients lacking immuno-nutrition data will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights that improve preoperative care and outcomes for patients with advanced gastric cancer.
How similar studies have performed: Other studies have indicated the importance of immune and nutrition indices in cancer prognosis, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed adenocarcinoma * Received neoadjuvant (preoperative) chemotherapy or chemoradiotherapy * Diagnosed clinical advanced gastric cancer or esophagogastric cancer Exclusion Criteria: * Lack of immuno-nutrition data
Where this trial is running
Beijing, Beijing
- Peking University Cancer Hospital — Beijing, Beijing, China (Recruiting)
Study contacts
- Principal investigator: Jiafu Ji, M.D., Ph.D. — Peking University Cancer Hospital & Institute
- Study coordinator: Shuangxi Li, M.D., Ph.D.
- Email: lishx@hsc.pku.edu.cn
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.